NCT04705844 - Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) | Biotech Hunter

Timeline

Start Date

September 30, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions

Mild to Moderate COVID-19

Interventions

DRUG

Adalimumab

adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

DRUG

Placebo

placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)